drugset
drugset / Trial / NCT05525455

TT-816 As Monotherapy or in Combination with a PD-1 Inhibitor in Patients with Advanced Cancers (SEABEAM) (MK3475-E88)

NCT05525455 ↗

Phase 1/2 Terminated 9 enrolled Teon Therapeutics, Inc. Merck Sharp & Dohme LLC · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

A first-in-human study using TT-816 as a single agent and in combination with a PD-1 inhibitor in advanced cancers.

Timeline

Start
2022-08-29
Primary completion
2023-09-07
Completion
2023-09-07

Outcome

Outcome not reported

Stopped: “Company operational decision. Decision to stop study is not due to safety or efficacy concerns.”

Drugs

EvaluationDrugModalityDoseRoute
Subject TT-816 Unknown — Oral

Indications

cancer